Lilly chief exec affirms company is not for sale

Share this article:

Eli Lilly's chief executive said his company is not for sale, boasts a
healthy pipeline and plans on producing top growth for years to
come, during television appearance yesterday.
Sidney Taurel said on CNBC Thursday that, historically, mergers
have not created shareholder value "in a sustainable fashion."
The chief executive also discussed a Dec. 2 lawsuit Lilly filed in Indiana district court seeking to stop Barr Pharmaceuticals from marketing a generic version of Zyprexa, Lilly's largest drug with sales of $233 million in the 12 months ending in September. "We really don't know when the judgment will come," Taurel said.
Speaking on pharma companies' relationships with consumers following the withdrawal of Vioxx, Taurel said, "This is the most challenging period I've seen in my career."                       

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.